

1 **UBR1 Promotes Sex-Dependent ACE2 Ubiquitination in Hypertension**

2 *Mona Elgazzaz^{1,2,5,6}, *Navya Lakkappa^{2,5}, Clara Berdasco^{2,5}, Uma Priya Mohan^{1,5},
3 Anna Nuzzo,¹ Luke Restivo¹, Alexa Martinez,¹ Amy Scarborough,¹ Jessie J. Guidry²,
4 Srinivas Sriramula^{2,7}, Jiayi Xu^{2,8}, Hisham Daoud⁹, Michelle A. Mendiola Plá¹⁰, Dawn E.
5 Bowles¹⁰, Andreas M. Beyer¹¹, Franck Mauvais-Jarvis^{5,12}, Xiping Yue^{1,2}, Catalin M.
6 Filipeanu¹³ and #Eric Lazartigues^{1,2,3,4,5}

7
8 ¹Cardiovascular Center of Excellence, Departments of ²Pharmacology & Experimental
9 Therapeutics and ³Medicine, and ⁴Neuroscience Center of Excellence, Louisiana State
10 University Health Sciences Center, New Orleans, LA 70112, USA;

11 ⁵Southeast Louisiana Veterans Health Care System, New Orleans, LA 70119, USA;

12 ⁶Genetics Unit, Department of Histology and Cell Biology, Faculty of Medicine, Suez
13 Canal University, Ismailia, 41522, Egypt;

14 ⁷Department of Pharmacology and Toxicology, Brody School of Medicine at East
15 Carolina University, Greenville, NC 27834, USA;

16 ⁸Department of Physiology and Pathophysiology, Xi'an Jiaotong University, School of
17 Medicine, Xi'an, 710061, China;

18 ⁹School of Computer and Cyber Sciences, Augusta University, Augusta, GA 30901,
19 USA

20 ¹⁰Division of Surgical Sciences, Department of Surgery, Duke University, Durham, NC
21 27710, USA;

22 ¹¹Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA;

23 ¹²Deming Department of Medicine, Tulane University, New Orleans, LA 70112, USA;

24 ¹³Department of Pharmacology, Howard University, Washington, DC 20059, USA.

25

26 *Both authors contributed equally.

27

28 Running title: ACE2 ubiquitination in hypertension

29

30 Number of words: 6270

31

32

33 #Correspondence to:

34 Dr. Eric Lazartigues, PhD; Louisiana State University Health, School of Medicine,
35 Cardiovascular Center of Excellence, 533 Bolivar Street, New Orleans, LA 70112. E-
36 mail: elazar@lsuhsc.edu

37

38 **Abstract**

39

40 Background: Angiotensin (Ang)-II impairs the function of the antihypertensive enzyme
41 ACE2 by promoting its internalization, ubiquitination and degradation thus contributing
42 to hypertension. However, few ACE2 ubiquitination partners have been identified and
43 their role in hypertension remains unknown.

44 Methods: Proteomics and bioinformatic analysis were used to identify ACE2
45 ubiquitination partners in the brain, heart, and kidney from Ang-II-infused C57BL6/J
46 mice from both sexes and validated the interaction between UBR1 and ACE2 in cells.
47 Central and peripheral UBR1 knockdown was then performed in male mice to
48 investigate its role in the maintenance of hypertension.

49 Results: Proteomics analysis from hypothalamus identified UBR1 as a potential E3
50 ligase promoting ACE2 ubiquitination. Enhanced UBR1 expression, associated with
51 ACE2 reduction, was confirmed in various tissues from hypertensive male mice and
52 human samples. Treatment of endothelial and smooth muscle cells with testosterone,
53 but not 17 β -estradiol, confirmed a sex-specific regulation of UBR1. In vivo silencing of
54 UBR1 using chronic administration of small interference RNA resulted in the restoration
55 of ACE2 levels in hypertensive males. A transient decrease in blood pressure following
56 intracerebroventricular, but not systemic, infusion was also observed. Interestingly,
57 UBR1 knockdown increased the brain activation of Nedd4-2, an E3 ligase promoting
58 ACE2 ubiquitination and reduced expression of SGK1, the kinase inactivating Nedd4-2.

59 Conclusions: These data demonstrate that UBR1 is a novel ubiquitin ligase targeting
60 ACE2 in hypertension. UBR1 and Nedd4-2 E3 ligases appear to work synergistically to
61 ubiquitinate ACE2. Targeting of these ubiquitin ligases may represent a novel strategy
62 to restore ACE2 compensatory activity in hypertension.

63

64 **Keywords:** ACE2, renin-angiotensin system, hypertension, ubiquitin, sex differences.

65

66 **Nonstandard Abbreviation and Acronyms:**

- 67
- 68 **ACE2** Angiotensin Converting Enzyme 2
- 69 **Ang-II** Angiotensin II
- 70 **Ang-(1-7)** Angiotensin (1-7)
- 71 **ANOVA** Analysis of variance
- 72 **AT₁R** Ang-II type 1 receptor
- 73 **BP** Blood pressure
- 74 **DHT** dihydrotestosterone
- 75 **DBDi** androgen receptor (AR) DNA-binding domain inhibitor
- 76 **E1** Ubiquitin-activating enzymes
- 77 **E2** Ubiquitin-conjugating enzymes
- 78 **E3** Ubiquitin protein ligases
- 79 **ENaC** Kidney epithelial Na⁺ channels
- 80 **HAEC** Human aortic endothelial cells
- 81 **LC-MS** Liquid chromatography–mass spectrometry
- 82 **MAP** Mean arterial pressure
- 83 **MDM2** Murine double minute 2
- 84 **MPP** Methypiperidinopyrazole
- 85 **Nedd4-2** Neural Precursor Cell Expressed Developmentally Down-Regulated Protein 4
- 86 **PHTPP** 4-[2-PHENYL-5,7-BIS(TRIFLUOROMETHYL)PYRAZOLO[1,5-A]PYRIMIDIN-3-
- 87 YL]PHENOL
- 88 **RAS** Renin-angiotensin system
- 89 **Skp2** S-Phase Kinase Associated Protein 2
- 90 **siRNA** Small interfering RNA
- 91 **SMC** Smooth muscle cell
- 92 **SGK1** Serum/Glucocorticoid-Regulated Kinase 1
- 93 **UBR1** Ubiquitin Protein Ligase E3 Component N-Recognin

94 **Introduction**

95 Angiotensin Converting Enzyme 2 (ACE2) is an important compensatory enzyme of the
96 renin-angiotensin system (RAS), converting the potent vasoconstrictor Angiotensin
97 (Ang)-II to the vasodilatory peptide Ang-(1-7).¹ We previously reported that ACE2 is the
98 target of Ang-II-induced internalization and degradation via the Ang-II type 1 receptor
99 (AT₁R), a process involving ubiquitination.²⁻⁴ Ubiquitination is a three-step enzymatic
100 process involving ubiquitin-activating enzymes (E1) binding to ubiquitin using a
101 molecule of ATP, followed by ubiquitin-conjugating enzymes (E2), carrying the ubiquitin
102 protein and conjugating with ubiquitin protein ligases (E3). E3 recognizes the protein to
103 be labeled and catalyzes the transfer of ubiquitin to the target protein. The pathway
104 continues until the target protein has a desired chain of poly-ubiquitins which is then
105 subjected to lysosomal/proteasomal degradation.^{5,6} Ubiquitination plays an important
106 role in the development of hypertension.⁷ Indeed, Nedd4-2, that we recently implicated
107 in ACE2 ubiquitination,³ is a well-known E3 ligase controlling cell surface expression of
108 kidney epithelial Na⁺ channels (ENaC) via ubiquitin-mediated endocytosis and
109 lysosomal degradation.⁷ Mutations of ENaC have also been reported to interfere with
110 ubiquitination by Nedd4-2, resulting in Liddle syndrome, a monogenic hypertensive
111 condition.^{8,9} Expression of Nedd4-2 was enhanced in the hypothalamus of mice and
112 endothelial cell cultures following Ang-II treatment and associated with a decrease in
113 ACE2 while knockdown of Nedd4-2 restored ACE2 expression.³ Importantly, prevention
114 of ACE2 ubiquitination resulted in the maintenance of a GABAergic inhibitory input to
115 presympathetic neurons in the hypothalamus and a reduction of hypertension.
116 While our group was first to report that Ang-II treatment induces ACE2 internalization
117 and ubiquitination through an AT₁R-dependent mechanism,^{2,4} very few reports have
118 focused on ACE2 ubiquitination partners.¹ Murine double minute 2 (MDM2) E3 ligase
119 was the first enzyme shown to promote ACE2 ubiquitination, possibly contributing to the
120 development of pulmonary arterial hypertension.¹⁰ Another E3 ligase, S-Phase Kinase
121 Associated Protein 2 (Skp2), was reported to be upregulated by cigarette smoke
122 carcinogens, leading to ACE2 ubiquitination in lung epithelial cells.^{11,12} However,
123 despite more than two decades of research establishing ACE2 as a critical player for
124 cardiovascular regulation, and several recent studies related to SARS-CoV-2 infection,¹

125 there is limited knowledge about the enzymes and mechanisms controlling ACE2
126 ubiquitination and the overall implications for cardiovascular regulation.

127 Incertitude also persists regarding sex differences in ACE2 expression and activity.
128 Early work in rodents showed that ACE2 expression^{13,14} and activity¹⁵ are tissue-
129 specific, higher in male kidneys and under the control of estrogens, while others
130 reported no sex difference. Estrogens and testosterone are well known to affect the
131 expression and activity of RAS components, contributing to sex differences in
132 cardiovascular outcomes.^{16,17} Estrogens have also been reported to upregulate the
133 protective Ang-(1-7)/ACE2/Mas1R/AT₂R,¹⁸ notably by increasing ACE2 gene
134 expression.¹⁹ In humans, studies have shown differential smooth muscle cells
135 expression of ACE2 in the airways of males and females. Clinical studies also reported
136 that higher levels of circulating soluble ACE2, previously shown by us to be a marker of
137 disease,^{20,21} were associated with the male sex, cardiovascular disease, diabetes, and
138 age; although increased ACE2 shedding does not imply sex differences at baseline.^{22,23}
139 Hence, sex differences in ACE2 expression are still poorly understood and the effect of
140 sex hormones on ACE2 ubiquitination in normotensive and hypertensive conditions has
141 not been investigated.

142 In the current study, we identified UBR1, an E3 ligase part of the N-end rule proteolytic
143 pathway of the ubiquitin system, as a sex-dependent regulator of ACE2 expression in
144 hypertension. We further report that the knockdown of UBR1 prevented ACE2
145 degradation, which supports its role in ACE2 ubiquitination and could lay the foundation
146 for new therapeutic strategies to prevent the loss of ACE2 compensatory activity in
147 hypertension.

148

149 **Methods**

150 The authors declare that all supporting data are available within the article and in the
151 Data Supplement. A detailed Methods section is available in the Online Data
152 Supplement.

153

154 Experiments were conducted in adult C57BL6/J mice (8–12 weeks old, 20-25 g;
155 Jackson Laboratory, Bar Harbor, ME) from both sexes. Mice were housed in a

156 temperature- (~25 °C) and humidity-controlled facility under a 12-hour dark/light cycle,
157 fed standard mouse chow (Envigo, iOS Teklab Extruded Rodent Diet 2019S,
158 Huntingdon, UK) and water *ad libitum*. All procedures conformed to the National
159 Institutes of Health Guide for the Care and Use of Laboratory Animals and were
160 approved by the Louisiana State University Health Sciences Center (#3540), and the
161 Southeast Veterans Healthcare System (#620) Institutional Animal Care and Use
162 Committees. Cardiac samples were obtained from The Medical College of Wisconsin
163 (IRB # PRO00010828) and Duke University (IRB # PRO00005621).

164

165 **Results**

166 **UBR1 Ubiquitin ligase is predicted to interact with ACE2 in hypertension.**

167 To identify ACE2 ubiquitination partners in hypertension, a proteomic analysis was
168 initially performed as reported previously.²⁴ Following 4 weeks of Ang-II infusion, the
169 hypothalamus was isolated and underwent proteomic analysis using Liquid
170 chromatography-mass spectrometry (LC-MS) with a focus on ubiquitination-related
171 proteins (Figure 1A). Based on abundance score, our data show an upregulation of the
172 E3 ligase UBR1 in Ang-II- induced hypertension in wild type mice hypothalamus (Figure
173 1B and Table S1). To investigate whether ACE2 could be a potential target for UBR1,
174 we used bioinformatic tools to evaluate the interaction between ACE2 and UBR1. Using
175 the Biological General Repository for Interaction Datasets (BioGRID) to explore curated
176 interactions between ACE2 and ubiquitin ligases,²⁵ multiple ubiquitin ligases were
177 shown to interact with ACE2 in humans, among which is UBR1 (Figure 1C).

178 ACE2 ubiquitination was further investigated in hypertension induced by Ang-II infusion
179 in both male and female mice. There was no significant blood pressure (BP) or heart
180 rate difference between male and female mice before Ang-II treatment (Figure 1D and
181 S1). Ang-II treatment resulted in a significant rise in BP that plateaued by the 4th week
182 of infusion. Hypertension was significantly higher in males than in females in both active
183 and resting phases (Figure 1D).

184

185 **Sex hormones regulate the expression of UBR1 and ACE2.**

186 Protein expression for UBR1 and ACE2 was assessed in the mouse brain (Figure 2A),
187 heart (Figure 2B) and kidneys (Figure 2C). We observed that male mice treated with
188 Ang-II showed a 2 to 3-fold increase in UBR1 levels in those tissues. Although UBR1
189 expression trended to an increase in females, it only reached significance in males.
190 ACE2 protein expression was significantly higher in males, notably in the brain (Figure
191 2E), while similar in the kidney for both sexes (Figure 2G). Although these higher levels
192 were not significant in the mouse heart (Figure 2F), data from human left ventricles
193 (Figure 2H) confirmed the elevated level in males. Ang-II treatment dramatically
194 reduced ACE2 expression, notably in the male brain (Figure 2E) with limited (Figure 2G)
195 or no impact (Figure 2E,F) in females. Together, these data suggest that Ang-II-induced
196 upregulation of UBR1 in males could contribute to the downregulation of ACE2. To
197 assess the clinical relevance of UBR1 in human hypertension, we evaluated left
198 ventricle cardiac samples from rejected donor hearts (Males: 47.5 ± 2.5 , Females: 43.8
199 ± 2.1 years old, $n=6$ /group, Table S2) with or without hypertension. As observed in mice,
200 ACE2 expression was higher in male normotensive donors (Figure 2H) and decreased
201 with hypertension. UBR1 protein levels were strongly upregulated in hypertensive
202 donors (Figure 2D), regardless of sex, but were associated with a decrease in ACE2
203 protein in males only (Figure 2H). Together, these data confirm that UBR1 upregulation
204 and the concomitant ACE2 downregulation observed in our preclinical model is
205 recapitulated in hypertensive subjects.

206

207 **UBR1 contributes to Ang-II-mediated ACE2 downregulation.**

208 To assess causality between UBR1 upregulation and ACE2 downregulation, primary
209 human aortic endothelial cells (HAEC) were transfected with a UBR1 siRNA which led
210 to a dose-dependent upregulation of ACE2 (Figure 3A). Pre-treatment with UBR1
211 siRNA produced a significant knockdown of UBR1 expression ($***P<0.001$), associated
212 with a parallel increase in ACE2 levels ($**P<0.01$), demonstrating that UBR1
213 constitutively regulates ACE2 expression. As observed in mice (Figure 2), Ang-II
214 treatment of HAEC led to a significant upregulation of UBR1, associated with a
215 reduction of ACE2 protein levels (Figure 3B; $***P<0.001$). Immunolabeling (Figure 3C)
216 showed that in baseline conditions ACE2 is expressed on the cell surface of HAEC

217 while UBR1 is located throughout the cell surface and cytoplasm. Upon treatment with
218 Ang-II, ACE2 was internalized in the cytoplasm but also in the nucleus where it strongly
219 co-localized with UBR1. Importantly, silencing of UBR1 prevented not only prevented
220 the Ang-II mediated upregulation of this E3 ligase but also resulted in an increase in
221 ACE2 levels (Figure 3B; ***P<0.001). These data suggest that UBR1 is critical for Ang-
222 II-mediated downregulation of ACE2. Since UBR2 has been shown to functionally
223 overlap with UBR1, the possibility that UBR2 could also ubiquitinate ACE2 was further
224 investigated. As suspected, transfection with UBR2 in HEK293T cells reduced ACE2
225 expression and activity (Figure S2 in data supplement) but this effect was independent
226 of Ang-II. Together, these data confirm that UBR1 is a newly identified mediator of
227 ACE2 ubiquitination.

228

229 **Role of sex hormones in UBR1 expression**

230 To further address the role of sex hormones on ACE2 ubiquitination by UBR1, we
231 expanded our experiments to HAEC and smooth muscle cells (SMC) to test for possible
232 cell specificity. Similar to the lack of UBR1 upregulation in female mice (Figure 2), 17 β -
233 estradiol treatment failed to increase UBR1 expression in HAEC (Figure 4A,B) or SMC
234 (Figure 4A,C), in the presence or absence of Ang-II. While 17 β -estradiol did not affect
235 ACE2 expression (Figure 4A,E) in HAEC, blockade of either alpha or beta estrogen
236 receptors (using MPP and PHTPP, respectively) prevented the Ang-II mediated
237 upregulation of UBR1 and concomitant downregulation of ACE2 (Figure 4A,B,D) in
238 HAEC, suggesting that 17 β -estradiol might have a synergistic action with Ang-II on
239 UBR1 expression. Unlike 17 β -estradiol, DHT alone increased UBR1 expression in
240 SMC, but not in HAEC (Figure 4A-C). In both cells, this was associated with reduced
241 ACE2 expression independently of Ang-II (Figure 4A,D,E). While androgen receptor
242 blocker flutamide was ineffective, likely due to incomplete prevention of DNA binding,
243 these responses could be prevented by the androgen receptor DNA binding domain
244 inhibitor (DBDi). Together, these data show that male sex hormones appear to
245 upregulate UBR1 and simultaneously reduce ACE2 in a cell specific manner while 17 β -
246 estradiol has no direct impact on UBR1.

247

248 **UBR1 knockdown restores ACE2 levels in hypertensive mice.**

249 Based on our observations that UBR1 is only upregulated in males, we proceeded to
250 investigate the role of UBR1 in ACE2 ubiquitination and hypertension. C57Bl6/J males
251 (12-week-old, n=5/group) were chronically infused with Ang-II for 4 weeks while treated
252 centrally or peripherally to achieve UBR1 knockdown (Figure 5A). UBR1 silencing
253 following the establishment of hypertension had no immediate effect when administered
254 centrally but was associated with an increase in BP in the first week of treatment, when
255 infused peripherally (Figure 5B). A transient reduction in BP occurred in the central
256 UBR1 siRNA group after 3 weeks of UBR1 knockdown (Figure 5B,C), most notably in
257 the resting phase of the nycthemeral cycle. In both peripheral and central UBR1 siRNA
258 groups, Ang-II-induced upregulation of UBR1 was blunted (Figure 6A), and this was
259 paralleled with a restoration of ACE2 protein levels in the hypothalamus (Figure 6B).
260 Interestingly, the Ang-II mediated upregulation of UBR1 was associated with an
261 increase in another E3 ligase expression, Nedd4-2 (Figure 6C), its inactivated form,
262 phosphorylated Nedd4-2 (Figure 6D,E) and the kinase responsible for its inactivation,
263 serum and glucocorticoid-regulated kinase 1 (SGK1, Figure 6F). The activation of
264 Nedd4-2 was evidenced by a decrease in phosphorylated Nedd4-2 relative to total
265 Nedd4-2 in UBR1 siRNA groups (Figure 6 C-E). Based on these observations, mice
266 were transfected *icv* with a lentivirus encoding a scrambled or Nedd4-2 shRNA (Figure
267 S3 in data supplement). While baseline BP was not affected by the treatment, a blunted
268 hypertension was noted early on post Ang-II infusion. However, this reduction of
269 hypertension did not persist and was gone by the third week of Ang-II treatment. To
270 further understand the mechanism of Nedd4-2 activation, we measured the protein
271 expression of SGK1, the kinase responsible for Nedd4-2 phosphorylation. Indeed,
272 SGK1 protein levels were also reduced in UBR1 siRNA treated groups, supporting the
273 overall activation of Nedd4-2 in UBR1 knockdown mice (Figure 6F).

274

275 **Discussion**

276 Although ACE2 was discovered in 2000, it took almost 15 years for the first ACE2
277 ubiquitination data to be reported.² MDM2 was then identified as the first E3 ligase
278 targeting ACE2¹⁰ and our group recently reported the role of Nedd4-2 in ACE2

279 ubiquitination.³ Using a proteomics discovery approach, followed by a multilayer's
280 validation process, we now report the identification of UBR1 as a the first E3 ligase from
281 the N-end rule pathway to ubiquitinate ACE2. Moreover, our data show that UBR1 is
282 differentially expressed during hypertension and regulated in a sex-dependent manner.
283 Our group previously reported that upon Ang-II treatment, ACE2 moves from the cell
284 surface to the lysosomes, followed by degradation in lysosomes, leading to a loss of
285 ACE2 expression and compensatory activity in diseases such as hypertension.² This
286 process involving ubiquitination is dependent on AT₁R, and was also observed in the
287 case of S1 spike protein (component of SARS-CoV-2 envelope)-induced ACE2
288 internalization.⁴ Ang-II activation of E3 ligases has long been recognized, notably for
289 Nedd4-2 and Cullin3.⁷ Expression of ACE2 has also been shown to modulate the levels
290 of E3 ligases, for example Smurf2 which is upregulated in the absence of ACE2.²⁶ The
291 COVID-19 pandemic provided a strong impetus to understand the mechanisms involved
292 in ACE2 post-translational regulation and several new ubiquitases have been
293 suggested,^{1,27} although most of them have not been associated with cardiovascular
294 regulation. The exception is our recent identification of Nedd4-2 as an E3 ligase
295 targeting ACE2 in pre-clinical and clinical hypertension.³ In this study we identified and
296 validated UBR1 as a new E3 ligase targeting ACE2. Additionally, we show a synergistic
297 interaction between Nedd4-2 and UBR1.

298 We observed that experimental and clinical hypertension is associated with an
299 upregulation of the E3 ligase UBR1, notably in males. In addition, although some cell
300 specificity was noted, all major tissues involved in BP regulation (*i.e.* brain, heart and
301 kidney) exhibited a similar sex difference. The role of UBR1 in ACE2 ubiquitination was
302 further confirmed in loss of function experiments showing that upon silencing UBR1,
303 Ang-II is no longer able to induce ACE2 internalization and degradation. UBR1 is an E3
304 ligase part of the N-end rule pathway, that binds and destabilizes N-terminal residues,
305 such as arginine, lysine, histidine, and bulky hydrophobic residues, promoting
306 polyubiquitination and the eventual degradation of the substrate. Although UBR1 was
307 primarily reported to modulate proteasomal degradation,²⁸ it also plays a role in the
308 quality control process, independent of the N-end rule pathway.²⁹ Interestingly, UBR1
309 also modulates proteolysis of the regulators of G-protein signaling, RGS4 and RGS5,

310 and differentially controls G-protein-coupled receptor signaling under normoxic/hypoxic
311 conditions.³⁰ Although mutations of the UBR1 gene have been associated with
312 Johanson-Blizzard syndrome, a rare genetic disorder that affects multiple organs,²⁸ to
313 date, there is little information about UBR1 suggesting it plays a role in cardiovascular
314 diseases. Previous work reported that pericytes infected by the Japanese encephalitis
315 virus could lead to a compromised blood-brain barrier mediated via UBR1.³¹ This is
316 relevant since experimental models of hypertension with increased Ang-II expression
317 increase blood-brain barrier permeability.³² In addition, ACE2 has also been reported to
318 contribute to blood-brain barrier homeostasis.³³ Although not explored in our study,
319 these observations could support a role for UBR1 in blood brain barrier leakage in
320 cardiovascular conditions. Our data show that UBR1 upregulation in hypertension was
321 not restricted to the brain but also apparent in the heart and kidney. Moreover, silencing
322 of UBR1 in endothelial cells not only prevented Ang-II-mediated downregulation of
323 ACE2 but was associated with an up-regulation of ACE2. Therefore, it is conceivable
324 that Ang-II-mediated upregulation of UBR1 in endothelial cells promotes ACE2
325 degradation, which in the brain could contribute to blood-brain barrier dysfunction and
326 the establishment of neurogenic hypertension. Downregulation of ACE2 from
327 endothelial cells in the heart and kidneys could also contribute to cardiovascular
328 disease progression through multiple mechanisms, including impaired endothelial
329 function.

330 Another finding from our study is the major role played by sex hormones on ACE2
331 expression and its ubiquitination partners. Clinical and pre-clinical studies have reported
332 opposite effects of sex hormones on ACE2 activity and expression.³⁴⁻³⁸ In line with our
333 observations, ACE2 expression is thought to be lower in females than males in multiple
334 cell types, tissues and species,^{34,35,38} while gonadectomy reverses these findings.³⁷
335 However, unlike our findings, exposure to testosterone led to increased ACE2
336 expression in pulmonary cells from both males and females while 17 β -estradiol
337 downregulated ACE2.^{34,36} Intriguingly, expression levels of fascin-1, an actin bundling
338 protein that protects ACE2 against Ang-II downregulation,³⁹ inversely correlates with
339 estrogen receptor alpha expression,^{40,41} indicating that multiple steps in ACE2
340 internalization and degradation can be modulated by sex hormones. In our study, DHT

341 upregulated UBR1 expression in SMC but not in endothelial cells, and this was
342 associated with a reduction of ACE2. This sex specificity is further supported by a
343 previous report showing that UBR1 promotes the degradation of the androgen
344 receptor.⁴² To the best of our knowledge, the present study is the first to show the
345 impact of sex hormones on ACE2 ubiquitination.

346
347 Our validation experiments in cells clearly show the co-dependence between Ang-II and
348 UBR1, with Ang-II promoting UBR1 upregulation and its inability to induce ACE2
349 downregulation when UBR1 has been silenced. Yet, some key questions remain
350 unanswered. Although our data show a massive upregulation of UBR1 in hypertensive
351 experimental conditions associated with increased Ang-II levels, as well as clinical
352 hypertension, we failed to see a major effect of UBR1 silencing on the development of
353 hypertension. This could be partially explained by the concomitant upregulation of active
354 Nedd4-2 and possibly other pro-hypertensive E3 ligases which could have mitigated the
355 impact of UBR1 knockdown by inducing pro-hypertensive pathways. Although
356 associated with developmental abnormalities and cognitive deficits,⁴³ complete deletion
357 of UBR1 in mice is viable further supporting compensation by other UBR1 homologs, for
358 example UBR2, or other E3 ligases. While knockdown of UBR1 had only a modest
359 impact on hypertension, it was sufficient to restore ACE2 expression in the
360 hypothalamus. UBR1 knockdown induced a compensatory positive feedback triggering
361 Nedd4-2 activation which we speculate prevented the reduction of hypertension. A
362 similar lack of efficiency was also observed when Nedd4-2 knockdown in the brain was
363 initiated prior to the development of hypertension (Figure S3 in data supplement), where
364 a transient drop in BP was observed followed by an increase in BP.

365 Interestingly, the type of ubiquitination driven by UBR1 is also thought to regulate
366 protein function, and as such, it has been involved in trafficking, activation of signaling
367 pathways, as well as synaptic plasticity of excitatory neurons.^{44,45}

368 Another unresolved question is the trafficking of ACE2 to the nucleus. Other members
369 of the RAS, notably AT₁R, have previously been identified in the nucleus, which forms
370 the basis for the existence of an intracellular RAS.⁴⁶ To our knowledge, there is no

371 previous report of ACE2 being identified in this organelle and further research is needed
372 to confirm this observation and determine if it is associated with a regulatory function.

373

374 In summary, the present study identifies a novel E3 ligase involved in ACE2
375 ubiquitination, taking place in various organs in experimental and clinical hypertension
376 and potentially capable of modulating ACE2 compensatory activity during the
377 development of cardiovascular diseases. Sex differences were further shown to play a
378 critical role in the expression levels of ACE2 and its ubiquitination. We propose that
379 ACE2 ubiquitination is an important mechanism leading to Ang-II-mediated
380 internalization of this enzyme and the loss of its compensatory activity. Inhibition of
381 UBR1 could be a new therapeutic strategy to prevent ACE2 ubiquitination in
382 hypertension.

383

384 **Novelty and Significance:**

385 **What is known?**

- 386 • ACE2 undergoes Ang-II-induced internalization via AT₁R, followed by
387 ubiquitination and lysosomal degradation during hypertension.
- 388 • Murine double minute 2 (MDM2) and S-Phase Kinase Associated Protein 2
389 (Skp2) and Nedd4-2 are E3 ligases that promote ACE2 ubiquitination.
- 390 • Estrogens and testosterone affect the expression and activity of RAS
391 components, contributing to sex differences in cardiovascular diseases.

392

393 **What new information does this article contribute?**

- 394 • UBR1 is a new E3 ligase involved in ACE2 ubiquitination in hypertension,
395 especially in males. The increase in UBR1 in hypertensive conditions is
396 differentially regulated by sex hormones.
- 397 • Ang-II-mediated ACE2 internalization, ubiquitination and degradation is taking
398 place within various tissues, including brain, heart and kidney in mice and is
399 clinically relevant to hypertensive conditions, as indicated by reduced ACE2
400 levels in cardiac samples from hypertensive patients.
- 401 • UBR1 works synergistically with Nedd4-2, another E3 ligase, to regulate ACE2
402 and BP levels.
- 403 • UBR1 could be a new therapeutic target to preserve ACE2 compensatory activity
404 in hypertension.
- 405 • This work provides new insights into the regulation of ACE2 and highlights
406 pathways that could be targeted for BP regulation.

407

408 **Acknowledgments**

409 The authors would like to thank the Wisconsin Donor Network and Versiti Blood Center
410 of Wisconsin organ procurement and Duke University teams for obtaining tissue from
411 rejected donor organs.

412

413 **Authors contributions**

414 M. Elgazzaz, N. Lakkappa, C. Berdasco, X. Yue, F. Mauvais-Jarvis, X. Yue, C.M.
415 Filipeanu and E. Lazartigues designed experiments. M. Elgazzaz, N. Lakkappa, C.
416 Berdasco, J.J. Guidry, S. Sriramula, J. Xu, U.P. Mohan, L. Restivo, A. Martinez, A.
417 Scarborough, X. Yue, and H. Daoud performed the experiments. A.M. Beyer, M.A.
418 Mendiola and D.E. Bowles contributed de-identified patient samples. M. Elgazzaz, N.
419 Lakkappa, X. Yue, C.M. Filipeanu and E. Lazartigues wrote the manuscript. All authors
420 contributed to manuscript revision.

421

422 **Sources of Funding**

423 This work was supported in part by research grants from the National Institutes of
424 Health (NIH) HL150592 to EL and CMF, COBRE P30GM106392, the Department of
425 Veterans Affairs BX004294 to EL and the Research Enhancement Program at LSU
426 Health-NO. FMJ was supported by grants from the NIH (DK074970) and the department
427 of Veterans Affairs BX005218.

428

429 **Disclosures**


430 None.

431

432 **Figure Legends**

433


434



435

436 **Figure 1: UBR1 is upregulated in hypertension and interacts with ACE2.**

437 (A) Hypothalami collected from sham- or Ang-II-treated C57Bl6/J male and female mice
 438 were subjected to proteomic analysis using Liquid chromatography–mass spectrometry
 439 (LC-MS). (B) Proteomics abundance scores of ubiquitin ligase proteins measured by
 440 LC-MS in hypertensive and normotensive mice. (C) Ubiquitin ligase system proteins
 441 interacting with ACE2 according to The Biological General Repository for Interaction
 442 Datasets (BioGRID; <https://thebiogrid.org/> last accessed on February 10, 2024),
 443 showing ACE2 interacting proteins belonging to the ubiquitin proteasome system. (D)
 444 Systolic and diastolic BP were recorded in C57Bl6/J male (blue) and female (magenta)
 445 mice at baseline (solid bars) and four weeks after Ang-II (hatched bars) infusion (n=7-
 446 8/group) during the active (moon icon and shaded area) and resting phases (sun icon).
 447 Data are shown as mean ±SEM. Statistical significance: Two-way analysis of variance
 448 (ANOVA): *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001 vs. respective controls.



449


450 **Figure 2: UBR1 and ACE2 expression are differentially regulated by sex**
 451 **hormones in Ang-II-mediated hypertension.** Expression of UBR1 (A-C) and ACE2
 452 (E-G) was assessed in the mouse hypothalamus, heart, and kidney (n= 6-8/group) after
 453 4 weeks of Ang-II infusion and in human cardiac left ventricle samples (D,H).
 454 Representative immunoassays for UBR1, ACE2 and GAPDH samples from Caucasian
 455 and Black donors (n=6-7/group) (D,H). Data are shown as mean \pm SEM. Statistical
 456 significance: Two-way analysis of variance (ANOVA): ****P<0.0001, **P<0.01 and
 457 *P<0.05. Abbreviations: NT, normotensive; HT, hypertensive.

458

459


460

461




462

463 **Figure 3: UBR1 contributes to Ang-II mediated ACE2 degradation.** Human aortic
 464 endothelial cells (HAEC) were pre-treated with control (scramble) or UBR1 siRNA for 6
 465 hours before exposure to Ang-II (100 nM) for 4 hours. Capillary Western Blot showing a
 466 UBR1 siRNA dose-response increase in UBR1 protein level and decrease in ACE2
 467 levels **(A)**. Capillary Western Blot showing a restoration of ACE2 levels following the
 468 knockdown of HAEC with UBR1 siRNA **(B)**. GFP-labeled ACE2 (Green) localizes at the
 469 plasma membrane in control cells and internalizes to the cytoplasm after Ang-II
 470 treatment. Texas red-labelled UBR1 is present throughout the cell and colocalizes with
 471 ACE2 mostly in the nucleus (DAPI, blue) following Ang-II treatment **(C)**. Data are shown
 472 as mean \pm SEM (n=3, in triplicate). Statistical significance: One-way analysis of variance
 473 (ANOVA) followed by Bonferroni test for multiple comparisons, *P<0.05,
 474 **P<0.01, ***P<0.001, ****P<0.0001



476

477 **Figure 4: Sex hormones regulation of UBR1.** Protein expression of UBR1 and ACE2
 478 in human aortic endothelial cells (A,B) and smooth muscle cells (C,D). Expression was
 479 normalized to β-actin and β-tubulin housekeeping proteins. MPP
 480 (Methylpiperidinopyrazole): selective estrogen receptor alpha blocker; PHTPP: selective
 481 estrogen receptor β antagonist; DHT: dihydrotestosterone; DBDi: DNA binding domain
 482 inhibitor. One way ANOVA followed by Bonferroni test for multiple comparisons,
 483 *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. N=4-6/group.




484

485

486 **Figure 5: UBR1 siRNA Infusion in Hypertensive Mice.** Experimental timeline of
 487 UBR1 siRNA infusion (A). Weekly MAP recording in mice infused with Ang-II combined
 488 with ICV or subcutaneous UBR1 siRNA (B). Summary data showing the average MAP
 489 per week in different groups (C). One-way ANOVA. * $P < 0.05$, **** $P < 0.0001$, $n = 4-15$ /gro-
 490 up.

491




492
 493 **Figure 6: Protein Expression in UBR1 siRNA-Infused Hypertensive Mice.** Capillary
 494 Western showing protein levels in the hypothalamus for UBR1 (A, ~230 kDa), ACE2 (B,
 495 ~140 kDa), Nedd4-2 (C, ~130 kDa), pNedd4-2 (D, ~130 kDa), pNedd4-2 to Nedd4-2
 496 ratio (E), and SGK1 (F, ~49 kDa) in various treatment groups. TP: total protein. One-
 497 way analysis of variance (ANOVA) followed by Bonferroni test for multiple comparisons,
 498 ****P<0.0001; ***P<0.001; **P<0.001; *P<0.05, n=4-5/group.

499

500

501 **Graphical abstract: Ang-II promotes ACE2 ubiquitination and hypertension.** Ang-II
502 binding to AT₁R is associated with upregulation of the E3 ligases UBR1 and Nedd4-2,
503 mostly in males. UBR1 and enhanced active Nedd4-2 both contribute to ACE2
504 polyubiquitination eventually leading to ACE2 degradation, the loss of compensatory
505 activity and hypertension.

506



507

508 **References**

- 509 1. Elgazzaz M, Filipeanu C, Lazartigues E. The 2023 Lewis K. Dahl Memorial
510 Lecture: Angiotensin-Converting Enzyme 2 Posttranslational Modifications-
511 Implications for Hypertension and SARS-CoV-2 Infection. *Hypertens Dallas Tex*
512 *1979*. 2024;
- 513 2. Deshotels MR, Xia H, Sriramula S, Lazartigues E, Filipeanu CM. Angiotensin II
514 Mediates Angiotensin Converting Enzyme Type 2 Internalization and Degradation
515 Through an Angiotensin II Type I Receptor-Dependent Mechanism. *Hypertension*.
516 2014;64:1368–1375.
- 517 3. Mohammed M, Ogunlade B, Elgazzaz M, Berdasco C, Lakkappa N, Ghita I, Guidry
518 J. J, Sriramula S, Xu J, Restivo L, Mendiola-Pla MA, Bowles D, Beyer AM, Yue X,
519 Lazartigues E, Filipeanu CM. Nedd4-2 upregulation is associated with ACE2
520 ubiquitination in hypertension. *Cardiovasc Res*. 2023;119:2130–2141.
- 521 4. Ogunlade BO, Lazartigues E, Filipeanu CM. Angiotensin Type 1 Receptor-
522 Dependent Internalization of SARS-CoV-2 by Angiotensin-Converting Enzyme 2.
523 *Hypertension*. 2021;77:e42–e43.
- 524 5. Tai HC, Schuman EM. Ubiquitin, the proteasome and protein degradation in
525 neuronal function and dysfunction. *Nat Rev Neurosci*. 2008;9:826–38.
- 526 6. Clague MJ, Urbé S. Ubiquitin: same molecule, different degradation pathways.
527 *Cell*. 2010;143:682–5.
- 528 7. Yamazaki O, Hirohama D, Ishizawa K, Shibata S. Role of the Ubiquitin Proteasome
529 System in the Regulation of Blood Pressure: A Review. *Int J Mol Sci*.
530 2020;21:5358.
- 531 8. Van Huysse JW, Amin MS, Yang B, Leenen FH. Salt-induced hypertension in a
532 mouse model of Liddle syndrome is mediated by epithelial sodium channels in the
533 brain. *Hypertension*. 2012;60:691–6.
- 534 9. Snyder PM, Price MP, McDonald FJ, Adams CM, Volk KA, Zeiher BG, Stokes, Jb,
535 Welsh MJ. Mechanism by which Liddle’s syndrome mutations increase activity of a
536 human epithelial Na⁺ channel. *Cell*. 1995;83:969–978.
- 537 10. Shen H, Zhang J, Wang C, Jain PP, Xiong M, Shi X, Lei Y, Chen S, Yin Q,
538 Thistlethwaite PA, Wang J, Gong K, Yuan ZY, Yuan JX, Shyy JY. MDM2-Mediated
539 Ubiquitination of ACE2 Contributes to the Development of Pulmonary Arterial
540 Hypertension. *Circulation*. 2020;
- 541 11. Asmamaw MD, Liu Y, Zheng YC, Shi XJ, Liu HM. Skp2 in the ubiquitin-proteasome
542 system: A comprehensive review. *Med Res Rev*. 2020;40:1920–1949.

- 543 12. Wang G, Zhao Q, Zhang H, Liang F, Zhang C, Wang J, Chen Z, Wu R, Yu H, Sun
544 B, Guo H, Feng R, Xu K, Zhou G. Degradation of SARS-CoV-2 receptor ACE2 by
545 the E3 ubiquitin ligase Skp2 in lung epithelial cells. *Front Med.* 2021;15:252–263.
- 546 13. Ji H, Menini S, Zheng W, Pesce C, Wu X, Sandberg K. Role of angiotensin-
547 converting enzyme 2 and angiotensin(1-7) in 17beta-oestradiol regulation of renal
548 pathology in renal wrap hypertension in rats. *Exp Physiol.* 2008;93:648–57.
- 549 14. Liu J, Ji H, Zheng W, Wu X, Zhu JJ, Arnold AP, Sandberg K. Sex differences in
550 renal angiotensin converting enzyme 2 (ACE2) activity are 17beta-oestradiol-
551 dependent and sex chromosome-independent. *Biol Sex Differ.* 2010;1:6.
- 552 15. Bhatia K, Zimmerman MA, Sullivan JC. Sex differences in angiotensin-converting
553 enzyme modulation of Ang (1-7) levels in normotensive WKY rats. *Am J Hypertens.*
554 2013;26:591–8.
- 555 16. Colafella KMM, Denton KM. Sex-specific differences in hypertension and
556 associated cardiovascular disease. *Nat Rev Nephrol.* 2018;14:185–201.
- 557 17. Medina D, Mehay D, Arnold AC. Sex differences in cardiovascular actions of the
558 renin-angiotensin system. *Clin Auton Res.* 2020;30:393–408.
- 559 18. Bukowska A, Spiller L, Wolke C, Lendeckel U, Weinert S, Hoffmann J, Bornfleth P,
560 Kutschka I, Gardemann A, Isermann B, Goette A. Protective regulation of the
561 ACE2/ACE gene expression by estrogen in human atrial tissue from elderly men.
562 *Exp Biol Med Maywood.* 2017;242:1412–1423.
- 563 19. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S.
564 Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome
565 Coronavirus Infection. *J Immunol.* 2017;198:4046–4053.
- 566 20. Xia H, Sriramula S, Chhabra K, Lazartigues E. Brain ACE2 Shedding Contributes
567 to the Development of Neurogenic Hypertension. *Circ Res.* 2013;113:1087–1096.
- 568 21. Xu J, Sriramula S, Xia H, Moreno-Walton L, Culicchia F, Domenig O, Poglitsch M,
569 Lazartigues E. Clinical Relevance and Role of Neuronal AT1 Receptors in
570 ADAM17-Mediated ACE2 Shedding in Neurogenic Hypertension. *Circ Res.*
571 2017;121:43–55.
- 572 22. Wallentin L, Lindbäck J, Eriksson N, Hijazi Z, Eikelboom JW, Ezekowitz MD,
573 Granger CB, Lopes RD, Yusuf S, Oldgren J, Siegbahn A. Angiotensin-converting
574 enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts
575 of patients with atrial fibrillation. *Eur Heart J.* 2020;41:4037–4046.
- 576 23. Sama IE, Ravera A, Santema BT, van Goor H, Ter Maaten JM, Cleland JGF,
577 Rienstra M, Friedrich AW, Samani NJ, Ng LL, Dickstein K, Lang CC, Filippatos G,
578 Anker SD, Ponikowski P, Metra M, van Veldhuisen DJ, Voors AA. Circulating
579 plasma concentrations of angiotensin-converting enzyme 2 in men and women with

- 580 heart failure and effects of renin-angiotensin-aldosterone inhibitors. *Eur Heart J.*
581 2020;41:1810–1817.
- 582 24. Yue X, Guidry JJ. Differential Protein Expression Profiles of Bronchoalveolar
583 Lavage Fluid Following Lipopolysaccharide-Induced Direct and Indirect Lung Injury
584 in Mice. *Int J Mol Sci.* 2019;20.
- 585 25. Oughtred R, Rust J, Chang C, Breitkreutz B, Stark C, Willems A, Boucher L, Leung
586 G, Kolas N, Zhang F, Dolma S, Coulombe-Huntington J, Chatr-aryamontri A,
587 Dolinski K, Tyers M. The BioGRID database: A comprehensive biomedical
588 resource of curated protein, genetic, and chemical interactions. *Protein Sci Publ*
589 *Protein Soc.* 2021;30:187–200.
- 590 26. Liu Z, Huang XR, Chen HY, Fung E, Liu J, Lan HY. Deletion of Angiotensin-
591 Converting Enzyme-2 Promotes Hypertensive Nephropathy by Targeting Smad7
592 for Ubiquitin Degradation. *Hypertension.* 2017;70:822–830.
- 593 27. Lazartigues E, Llorens-Cortes C, Danser AHJ. New Approaches Targeting the
594 Renin-Angiotensin System: Inhibition of Brain Aminopeptidase A, ACE2
595 Ubiquitination, and Angiotensinogen. *Can J Cardiol.* 2023;39:1900–1912.
- 596 28. Kim JG, Shin HC, Seo T, Nawale L, Han G, Kim BY, Kim SJ, Cha-Molstad H.
597 Signaling Pathways Regulated by UBR Box-Containing E3 Ligases. *Int J Mol Sci.*
598 2021;22.
- 599 29. Nillegoda NB, Theodoraki MA, Mandal AK, Mayo KJ, Ren HY, Sultana R, Wu K,
600 Johnson J, Cyr DM, Caplan AJ. Ubr1 and Ubr2 function in a quality control
601 pathway for degradation of unfolded cytosolic proteins. *Mol Biol Cell.*
602 2010;21:2102–16.
- 603 30. Lee MJ, Tasaki T, Moroi K, An JY, Kimura S, Davydov IV, Kwon YT. RGS4 and
604 RGS5 are in vivo substrates of the N-end rule pathway. *Proc Natl Acad Sci U S A.*
605 2005;102:15030–5.
- 606 31. Chen CJ, Ou YC, Li JR, Chang CY, Pan HC, Lai CY, Liao SL, Raung SL, Chang
607 CJ. Infection of pericytes in vitro by Japanese encephalitis virus disrupts the
608 integrity of the endothelial barrier. *J Virol.* 2014;88:1150–61.
- 609 32. Mowry FE, Peadar SC, Stern JE, Biancardi VC. TLR4 and AT1R mediate blood-
610 brain barrier disruption, neuroinflammation, and autonomic dysfunction in
611 spontaneously hypertensive rats. *Pharmacol Res.* 2021;174:105877.
- 612 33. DeOre BJ, Tran KA, Andrews AM, Ramirez SH, Galie PA. SARS-CoV-2 Spike
613 Protein Disrupts Blood-Brain Barrier Integrity via RhoA Activation. *J Neuroimmune*
614 *Pharmacol.* 2021;1–7.
- 615 34. Kalidhindi RSR, Borkar NA, Ambhore NS, Pabelick CM, Prakash YS, Sathish V.
616 Sex steroids skew ACE2 expression in human airway: a contributing factor to sex

- 617 differences in COVID-19? *Am J Physiol Lung Cell Mol Physiol*. 2020;319:L843-
618 l847.
- 619 35. Chen K, Bi J, Su Y, Chappell MC, Rose JC. Sex-Specific Changes in Renal
620 Angiotensin-Converting Enzyme and Angiotensin-Converting Enzyme 2 Gene
621 Expression and Enzyme Activity at Birth and Over the First Year of Life. *Reprod*
622 *Sci*. 2016;23:200–10.
- 623 36. Stelzig KE, Canepa-Escaro F, Schiliro M, Berdnikovs S, Prakash YS, Chiarella SE.
624 Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated
625 airway epithelial cells. *Am J Physiol Lung Cell Mol Physiol*. 2020;318:L1280-l1281.
- 626 37. Dalpiaz PL, Lamas AZ, Caliman IF, Ribeiro RF, Abreu GR, Moyses MR, Andrade
627 TU, Gouvea SA, Alves MF, Carmona AK, Bissoli NS. Sex Hormones Promote
628 Opposite Effects on ACE and ACE2 Activity, Hypertrophy and Cardiac Contractility
629 in Spontaneously Hypertensive Rats. *PLoS ONE*. 2015;10:e0127515.
- 630 38. Pendergrass KD, Pirro NT, Westwood BM, Ferrario CM, Brosnihan KB, Chappell
631 MC. Sex differences in circulating and renal angiotensins of hypertensive mRen(2).
632 Lewis but not normotensive Lewis rats. *Am J Physiol Heart Circ Physiol*.
633 2008;295:H10-20.
- 634 39. Ogunlade B, Guidry JJ, Mukerjee S, Sriramula S, Lazartigues E, Filipeanu CM. The
635 Actin Bundling Protein Fascin-1 as an ACE2-Accessory Protein. *Cell Mol*
636 *Neurobiol*. 2020;Online ahead of print:1–9.
- 637 40. Rezaul K, Thumar JK, Lundgren DH, Eng JK, Claffey KP, Wilson L, Han DK.
638 Differential protein expression profiles in estrogen receptor-positive and -negative
639 breast cancer tissues using label-free quantitative proteomics. *Genes Cancer*.
640 2010;1:251–71.
- 641 41. Esnakula AK, Ricks-Santi L, Kwagyan J, Kanaan YM, DeWitty RL, Wilson LL, Gold
642 B, Frederick WA, Naab TJ. Strong association of fascin expression with triple
643 negative breast cancer and basal-like phenotype in African-American women. *J*
644 *Clin Pathol*. 2014;67:153–60.
- 645 42. Sultana R, Theodoraki MA, Caplan AJ. Specificity in the actions of the UBR1
646 ubiquitin ligase in the degradation of nuclear receptors. *FEBS Open Bio*.
647 2013;3:394–397.
- 648 43. An JY, Seo JW, Tasaki T, Lee MJ, Varshavsky A, Kwon YT. Impaired
649 neurogenesis and cardiovascular development in mice lacking the E3 ubiquitin
650 ligases UBR1 and UBR2 of the N-end rule pathway. *Proc Natl Acad Sci U S A*.
651 2006;103:6212–7.
- 652 44. Erpapazoglou Z, Walker O, Haguenuer-Tsapis R. Versatile roles of k63-linked
653 ubiquitin chains in trafficking. *Cells*. 2014;3:1027–88.

654 45. Kim S, Zhang Y, Jin C, Lee Y, Kim Y, Han K. Emerging roles of Lys63-linked
655 polyubiquitination in neuronal excitatory postsynapses. *Arch Pharm Res.*
656 2019;42:285–292.

657

658